Ultragenyx reports preliminary 2023 revenue $430-435M; guides 2024 revenue $500-530M

Ultragenyx Pharmaceutical Inc.

Preliminary 2023 total revenue $430-435M; Crysvita $325-330M, Dojolvi $70-71M.
2024 total revenue guidance $500-530M; Crysvita $375-400M, Dojolvi $75-80M.
Year-end 2023 cash ~$776M; 2024 net cash used in ops guided <$400M.
Phase 3 data readouts expected H1 2024 for GSDIa gene therapy (DTX401) and OI study enrollment completion.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ultragenyx Pharmaceutical Inc. reported fiscal year 2024 results: revenue $500 million to $530 million. Guidance initiated.

Period: fiscal year 2024
Revenue: $500 million to $530 million
Guidance: initiated
Result: guidance update

Exact text from the filing

2024 expected Total Revenue guidance between $500 million to $530 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ultragenyx Pharmaceutical Inc. reported fiscal year 2023 results: revenue $430 million to $435 million.

Period: fiscal year 2023
Revenue: $430 million to $435 million
Result: preliminary results

Exact text from the filing

Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $ 325 million to $330 million and Dojolvi® revenue of $70 million to $71 million

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Ultragenyx Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-002655

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.